Differential tissue expression of extracellular vesicle-derived proteins in prostate cancer

Diederick Duijvesz1,2 | Giovanny Rodriguez-Blanco3 | A. Marije Hoogland4,5 | Esther I. Verhoef4 | Lennard J. Dekker3 | Monique J. Roobol1 | Geert J.L.H. van Leenders4 | Theo M. Luider3 | Guido Jenster1

1Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
2Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
3Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
4Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
5Department of Pathology, Isala Clinics, Zwolle, The Netherlands

Correspondence
D. Duijvesz, MD, Department of Urology, Josephine Nefkens Institute, Be 330, Erasmus MC, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands.
Email: D.Duijvesz@cwz.nl

Abstract
Background: Proteomic profiling of extracellular vesicles (EVs) from prostate cancer (PCa) and normal prostate cell lines, led to the identification of new candidate PCa markers. These proteins included the nuclear exportin proteins XPO1 (also known as CRM1), the EV-associated PDCD6IP (also known as ALIX), and the previously published fatty acid synthase FASN. In this study, we investigated differences in expression of XPO1 and PDCD6IP in well-characterized prostate cancer cohorts using mass spectrometry and tissue microarray (TMA) immunohistochemistry to determine their diagnostic and prognostic value.

Methods: Protein fractions from 67 tissue samples (n = 33 normal adjacent prostate [NAP] and n = 34 PCa) were analyzed by mass spectrometry (nano-LC-MS-MS). Label-free quantification of EVs was performed to identify differentially expressed proteins between PCa and NAP. Prognostic evaluation of the candidate markers was performed with a TMA, containing 481 radical prostatectomy samples. Samples were stained for the candidate markers and correlated with patient information and clinicopathological outcome.

Results: XPO1 was higher expressed in PCa compared to NAP in the MS data analysis (P > 0.0001). PDCD6IP was not significantly higher expressed (P = 0.0501). High cytoplasmic XPO1 staining in the TMA immunohistochemistry, correlated in a multi-variable model with high Gleason scores (P = 0.002) and PCa-related death (P = 0.009).

Conclusion: High expression of cytoplasmic XPO1 shows correlation with prostate cancer and has added clinical value in tissue samples. Furthermore, as an extracellular vesicles-associated protein, it might be a novel relevant liquid biomarker.

KEYWORDS biomarker, extracellular vesicles, PDCD6IP, prostate cancer, tissue microarray, XPO1

Abbreviations: CRM1, chromosomal maintenance 1; CRPC, castration resistant prostate cancer; EVs, extracellular vesicles; FASN, fatty acid synthetase N; IHC, immunohistochemistry; LC, liquid chromatography; LFQ, label free quantification; MS, mass spectrometry; NAP, normal adjacent prostate; PCa, prostate cancer; PDCD6IP, programmed cell death 6 interacting protein; also known as ALIX; PSA, prostate specific antigen; RNA, ribonucleic acid; TMA, tissue microarray; TURP, transurethral resection of the prostate; XPO1, exportin-1.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2019 The Authors. The Prostate Published by Wiley Periodicals, Inc.
1 | INTRODUCTION

Biomarker discovery via extracellular vesicles (EVs; often referred to as exosomes) released by (cancer) cells, has been the focus of many research groups in the last decade.1,2 Based on their biogenesis and secretion pathway, they contain low-abundant, cancer-specific proteins, and RNAs that could be of interest in identifying novel biomarkers.3 With respect to prostate cancer (PCa), several EV-derived candidate biomarkers have been revealed.4–10

Although multiple markers have been proposed as candidates for several malignancies, the majority has been identified and validated in EVs derived from cell culture. Few of the candidate biomarkers have been validated on larger groups of patient samples. Because this validation step is rarely taken, it remains difficult to elucidate the full potential of EV markers, which limits its translation and clinical implementation.11,12

Our own efforts, by using state-of-the-art mass spectrometry, has led to the discovery of some candidate markers of which XPO1 (also known as CRM1), FASN, and PDCD6IP (also known as ALIX) were found to have the highest potential.7 The objective of this study was to investigate whether the PCa EV-associated expression could be reproduced in tissue analyses of larger cohorts of patients. Result for FASN has been published previously.13

2 | MATERIALS AND METHODS

2.1 | Mass spectrometry

Protein fractions from tissue RNA isolations with RNA-Bee of 67 PCa tissue samples (33 NAP and 34 PCa) were selected and stored at −80°C as described in Rodriguez et al.13 Samples were thawed and 50 µL precipitated with cold acetone and microcentrifugation. After 10 minutes, the supernatant was removed and the pellet washed twice with cold acetone. The supernatant was removed and 50 µL of 0.1% RapiGest (Waters Corporation, Milford, MA) in 50 mM NH₄HCO₃ was added to the protein pellet. The protein pellet was dissolved by external sonification for 5 minutes at 70% amplitude at 80°C as described in Rodriguez et al.13 Samples were thawed and 50 µL precipitated with cold acetone and microcentrifugation. After 10 minutes, the supernatant was removed and the pellet washed twice with cold acetone. The supernatant was removed and 50 µL of 0.1% RapiGest (Waters Corporation, Milford, MA) in 50 mM NH₄HCO₃ was added to the protein pellet. The protein pellet was dissolved by external sonification for 5 minutes at 70% amplitude at room temperature (Digital Sonifier model 450, Branson, Danbury, CT). The proteins were reduced with 10 mM dithiothreitol at 60°C for 30 minutes. After cooling down to room temperature, it was alkylated with 50 mM iodoacetamide for 30 minutes, and digested overnight with 8 µL trypsin (Promega, Madison, WI). Subsequently, 6 µL of 5% TFA was added to inactivate digestion and incubated for 30 minutes at 37°C. Samples were centrifuged at maximum speed for 60 minutes at 4°C and the supernatant was transferred to new tubes. A total of 5 µL was diluted 40 times and subsequently transferred to LC vials for LC-MS analysis. Upon analysis, 2 µL was injected to the nano-LC. After preconcentration and washing of the sample it was loaded on to a C18 column (PepMap C18, 75 mm ID × 500 mm, 2 µm particle, and 100 Å pore size; Thermo Fisher Scientific, Bremen, Germany) using a linear 90 minutes gradient (4%-25% acetonitrile/ H₂O; 0.1% formic acid) at a flow rate of 250 nL/minute. The separation of the peptides was monitored by a UV detector (absorption at 214 nm). The nano-LC was coupled to a nanospray source of a Q-Exactive plus mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). Full scan MS spectra (m/z 400-1600) in profile mode were acquired in the Orbitrap with a resolution of 70 000 after the accumulation of an AGC target of 1 × 10⁶. The top 12 peptide signals (charge-state 2⁻ and higher) were isolated (1.6 Da window) and fragmented by HCD (higher-energy collision, normalized collision energy 28.0) and measured in the Orbitrap with an AGC target of 50 000 and a resolution of 17 500. Maximum fill times were 100 ms for the full scans and 60 ms for the MS/MS scans. The dynamic exclusion was activated, after the first time a precursor was selected for fragmentation it was excluded for a period of 30 seconds using a relative mass window of 10 ppm. Lock mass correction was activated to improve mass accuracy of the survey scan.

Label-free quantitation was performed using Progenesis LC-MS Software (version 3.0; Nonlinear Dynamics Ltd., Newcastle-upon-Tyne, UK) following our previously reported methodology.14,15 To get quantitative data, we selected only proteins identified by three or more peptides for statistical analysis of protein abundance between groups. Duplicates in identified sequences as a consequence of peak tailing were removed to avoid false positives. Technical replicates of each sample were randomly analyzed within the measurement period and no significant changes in the number of identified proteins were observed between replicates and quality control measurements.

2.2 | Tissue microarray

A tissue microarray (TMA) was constructed as published previously.16 Briefly, 481 men were selected from the European Randomized Study of Screening for prostate cancer (ERSPC), who had undergone radical prostatectomy for PCa.17 From each patient sample, three representative cores (diameter 0.6 mm) were taken and placed in nine paraffin blocks. Patient information and clinical follow data were recorded via the ERSPC protocol and stored in a central study database.

For immunohistochemical (IHC) staining the tissues slides were mounted on aminoacetylsilane coated glass slides (Starfrost, Berlin, Germany), deparaffinized with xylene and dehydrated in ethanol. The slides were placed in 0.3% hydrogen peroxide in PBS for 20 minutes to block endogenous peroxidase activity. Microwave pretreatment was performed for 15 minutes in tris (hydroxymethyl)aminomethane-ethylenediaminetetraacetic acid (pH 9.0). Subsequently, the slides were incubated with PDCD6IP (1:400), FASN (1:50), and XPO1 (1:50) antibodies, overnight at 4°C. The EnVision DAKO kit (DAKO, Glostrup, Denmark) was used for chromogenic visualization. Counterstaining was performed with hematoxylin, which was followed by dehydration and mounting in malinol (Chroma-Gesellschaft, Köringen, Germany).

Staining intensities of each antibody were scored independently by two investigators (DD, AMH) as negative (0; no staining), weak (1; only visible at high magnification), moderate (2; visible at low magnification), and strong (3; striking at low magnification).18
Based on previous IHC staining results, for XPO1 a score was assigned to both nuclear staining and cytoplasmic staining. For PDCD6IP only the cytoplasmic expression was scored. In cases of staining heterogeneity, the highest expression levels were used for statistical analysis. After scoring, the average intensity for the triplicate cores was calculated. When a core was missing or no cancer was observed, this respective case was excluded from the analysis. In a combined session consensus on expression value was reached in all cases.

Statistical association of staining intensities and clinic-pathological features (PSA at diagnosis, Gleason score (GS), pT-stage, surgical margins, biochemical recurrence, local recurrence, overall death, and PCa-related death) were performed with SPSS (version 17, SPSS Inc., Chicago, IL) by using Pearson’s $\chi^2$ tests and Student’s $t$ tests. A multivariable analysis was performed to determine the contribution of each individual variable. A $P < 0.05$ was considered to be statistically significant.

3 | RESULTS

3.1 | Protein expression by mass spectrometry

We previously published a list with proteins (n = 263) that were identified in EVs from normal prostate (PNT2C2 and RWPE-1) and Ca (VcAp and PC346c) cell lines by using mass spectrometry. From this list, 10 proteins were identified as higher expressed in Ca-derived EVs of which expression of 3 proteins (XPO1, FASN, and PDCD6IP) were further analyzed for EV and tissue expression. For a first validation, we compared the 263 proteins to a shotgun mass spectrometry database recently published which 34 Ca (n = 22 GS 6, n = 12 GS ≥ 7) and 33 NAP tissues were compared using label-free quantification. In this database, a total of 2865 proteins were identified from which 798 proteins were statistically significant differentially expressed between normal prostate and Ca (FDR < 0.01). When compared to the list of EV-derived proteins, 42 of these proteins showed overlap (Figure 1A and Table 1).

![Figure 1](wileyonlinelibrary.com)
### TABLE 1 Proteins that were significantly differentially expressed between extracellular vesicles (EVs) from prostate cancer (PCa) cells and non-PCa cells compared to MS-MS protein expression in PCa and NAP tissue

| Accession number | Peptide count | Unique peptides | Confidence score | ANOVA (p)   | Max fold change | Highest mean expression | Lowest mean expression |
|------------------|---------------|-----------------|------------------|-------------|----------------|------------------------|------------------------|
| **Higher expression in VCaP and PC346c PCa-derived EVs** |
| Fatty acid synthase (FASN) | P49327        | 103             | 98               | 147.44      | 0.000000       | 2.95                   | PCa NAP                 |
| Exportin-1 (XPO1) | O14980        | 7               | 7                | 7.92        | 0.000001       | 1.52                   | PCa NAP                 |
| Polyadenylate-binding protein 1 (PABPC1) | P11940        | 14              | 11               | 16.92       | 0.001511       | 1.43                   | NAP PCa                 |
| CD9 antigen (CD9) | P21926        | 4               | 4                | 7.98        | 0.050249       | 1.30                   | NAP PCa                 |
| Programmed cell death 6-interacting protein (PDCD6IP) | Q8WUM4        | 30              | 27               | 35.77       | 0.245175       | 1.10                   | PCa NAP                 |
| Elongation factor 1-α 2 (EEF1A2) | Q05639         | 13              | 5                | 17.92       | 0.235288       | 2.23                   | PCa NAP                 |
| Ubiquitin-60S ribosomal protein L40 (UBA52) | P62987        | 7               | 1                | 10.96       | 0.309769       | 3.36                   | PCa NAP                 |
| Basal cell adhesion molecule (BCAM) | P50895        | 11              | 10               | 12.95       | 0.472126       | 1.23                   | PCa NAP                 |
| Vacuolar protein sorting-associated protein 28 homolog (VPS28) | not identified by mass-spectrometry in PCa tissue |
| **Actin-related protein 3B (ACTR3B) not identified by mass-spectrometry in PCa tissue** |
| Annexin A2 (P07355) | P07355;A6NMY6 | 28              | 28               | 38.85       | 0.000000       | 1.50                   | NAP PCa                 |
| UDP-glucose 6-dehydrogenase (O60701) (UGDH) | O60701        | 24              | 22               | 31.86       | 0.000000       | 2.03                   | PCa NAP                 |
| Ras-related protein Rap-1A (P62834) (RAP1A) | P62834        | 8               | 1                | 8.92        | 0.000011       | 1.69                   | NAP PCa                 |
| 14-3-3 protein theta (P27348) (YWHAQ) | P27348        | 20              | 12               | 24.89       | 0.000201       | 1.33                   | PCa NAP                 |
| T-complex protein 1 subunit epsilon (P48643) (CCT5) | P48643        | 17              | 14               | 18.87       | 0.000301       | 1.43                   | PCa NAP                 |
| 78 kDa glucose-regulated protein (P11021) (HSPA5) | P11021        | 36              | 28               | 49.82       | 0.000304       | 1.47                   | PCa NAP                 |
| Chloride intracellular channel protein 1 (K000299) (CLIC1) | O00299        | 13              | 12               | 17.94       | 0.000486       | 1.22                   | PCa NAP                 |
| Keratin, type I cytoskeletal 9 (P35527) (KRT9) | P35527        | 4               | 4                | 3.93        | 0.000631       | 5.87                   | PCa NAP                 |
| 14-3-3 protein epsilon (P62258) (YWHAE) | P62258        | 22              | 19               | 24.87       | 0.010096       | 1.27                   | PCa NAP                 |
| Sodium/potassium-transporting ATPase subunit β-3 (P54709) (ATP1B3) | P54709        | 4               | 4                | 4.98        | 0.026991       | 1.16                   | PCa NAP                 |
| Ras-related protein Rab-10 (P61026) (RAB10) | P61026        | 6               | 3                | 6.98        | 0.028100       | 1.24                   | PCa NAP                 |
| Pyruvate kinase isozymes M1/M2 (P14618) (PKM2) | P14618        | 29              | 29               | 45.85       | 0.030393       | 1.10                   | NAP PCa                 |
| Ras-related protein Rab-1A (P62820) (RAB1A) | P62820        | 8               | 3                | 10.95       | 0.033276       | 1.19                   | PCa NAP                 |
| α-Enolase (P06733) (ENO1) | P06733        | 30              | 20               | 44.82       | 0.043735       | 1.22                   | PCa NAP                 |
| Hemoglobin subunit β (P68871) (HBB) | P68871;P69891;P69892 | 18              | 11               | 35.87       | 0.043867       | 1.53                   | NAP PCa                 |
| Peroxiredoxin-1 (Q06830) (PRDX1) | Q06380        | 15              | 11               | 19.92       | 0.083975       | 1.17                   | PCa NAP                 |
| ADP-ribosylation factor 1 (P84077) (ARF1) | P84077        | 10              | 3                | 11.96       | 0.132790       | 1.22                   | PCa NAP                 |

(Continues)
| Accession number | Peptide count | Unique peptides | Confidence score | ANOVA (p) | Max fold change | Highest mean expression | Lowest mean expression |
|------------------|---------------|-----------------|------------------|-----------|-----------------|------------------------|------------------------|
| Keratin, type II cytoskeletal 2 epidermal (P35908) | KRT2 | P35908 | 6 | 1 | 6.96 | 0.150597 | 1.24 | NAP | PCa |
| Sodium/potassium-transporting ATPase subunit β-1(P05026) | ATP1B1 | P05026 | 1 | 1 | 1.98 | 0.186607 | 1.10 | NAP | PCa |
| Catenin β-1(P35222) | CTNNB1 | P35222 | 19 | 13 | 21.91 | 0.190862 | 1.14 | PCa | NAP |
| Ras GTase-activating-like protein IQGAP1(P46940) | IQGAP1 | P46940 | 33 | 28 | 37.85 | 0.198229 | 1.12 | PCa | NAP |
| Ras-related C3 botulinum toxin substrate 1(P63000) | RAC1 | P63000 | 6 | 2 | 7.97 | 0.216742 | 1.14 | PCa | NAP |
| Phosphoglycerate kinase 1(P00558) | PGK1 | P00558 | 28 | 26 | 42.79 | 0.246349 | 1.06 | NAP | PCa |
| Sodium/potassium-transporting ATPase subunit α-1(P05023) | ATP1A1 | P05023 | 28 | 25 | 32.83 | 0.346299 | 1.07 | PCa | NAP |
| 14-3-3 protein beta/alpha(P31946) | YWHAB | P31946 | 15 | 7 | 19.93 | 0.370719 | 1.07 | PCa | NAP |
| Tubulin α-1A chain(Q71U36) | TUBA1A | Q71U36A6NHL2 | 25 | 2 | 37.82 | 0.377593 | 1.06 | PCa | NAP |
| Lactadherin(Q08431) | MFGE8 | Q08431 | 1 | 1 | 1.00 | 0.518547 | 1.37 | PCa | NAP |
| EH domain-containing protein 4(Q9H223) | EHD4 | Q9H223 | 8 | 6 | 7.95 | 0.533687 | 1.02 | PCa | NAP |
| Triosephosphate isomerase(P60174) | TPI1 | P60174 | 17 | 15 | 30.90 | 0.560817 | 1.05 | PCa | NAP |
| Importin subunit β-1(Q14974) | KPNB1 | Q14974 | 16 | 16 | 18.91 | 0.592615 | 1.04 | PCa | NAP |
| Basigin(P35613) | BSG | P35613 | 3 | 3 | 2.94 | 0.744475 | 1.03 | NAP | PCa |
| Junctional adhesion molecule A(Q9Y624) | F11R | Q9Y624 | 3 | 3 | 2.98 | 0.767732 | 1.07 | PCa | NAP |
| Protein DJ-1(Q99497) | PARK7 | Q99497 | 16 | 15 | 21.89 | 0.790992 | 1.01 | NAP | PCa |
| Adenosylhomocysteinase (P23526) | AHCY | P23526 | 20 | 18 | 23.85 | 0.906165 | 1.01 | NAP | PCa |
| Integrin α-6(P23229) | ITGA6 | not identified by mass-spectrometry in PCa tissue |
| Actin, aortic smooth muscle(P62736) | ACTA2 | not identified by mass-spectrometry in PCa tissue |
| Potassium-transporting ATPase α chain 2(P54707) | ATP12A | not identified by mass-spectrometry in PCa tissue |
| 4F2 cell-surface antigen heavy chain (P08195) | SLC3A2 | not identified by mass-spectrometry in PCa tissue |
| CD151 antigen(P48509) | CD151 | not identified by mass-spectrometry in PCa tissue |
| Coxsackievirus and adenovirus receptor (P78310) | CXADR | not identified by mass-spectrometry in PCa tissue |
Our previously identified candidate PCa-EV biomarkers XPO1 ($P < 0.0001$) and FASN ($P < 0.0001$) were higher expressed in PCa tissue, while PDCD6IP was borderline not significantly higher expressed ($P = 0.0501$) (Table 1; Figure 1B). Interestingly, polyadenylate-binding protein 1 (PABCP1) was higher expressed in PCa-derived EVs but showed significantly lower expression in PCa

### TABLE 1

| Peptide count | Unique peptides | Confidence score | ANOVA (p) | Max fold change | Lowest mean expression | Highest mean expression |
|---------------|-----------------|------------------|-----------|----------------|------------------------|------------------------|
| Prostaglandin F2 receptor negative regulator (Q9PB2) | not identified by mass-spectrometry in PCA tissue | | | | | |
| Putative heat shock protein HSP 90.β (Q54E7) | not identified by mass-spectrometry in PCA tissue | | | | | |
| Putative heat shock protein HSP 90.β (Q62Q8F0) | not identified by mass-spectrometry in PCA tissue | | | | | |
| Prostate cancer related death | | | | | | |
| Yes | n = 12 (10.7) | No | n = 74 (66.0) | Unknown | n = 26 (23.2) |

Abbreviation: NAP, normal adjacent prostate.

### TABLE 2

Patient characteristics and clinicopathological parameters of the prostate samples after treatment by radical prostatectomy ($n = 481$) as was published by Hoogland et al.

| Patient characteristics and clinicopathological parameters | Total number of patients (%) | Mean (variation) |
|-----------------------------------------------------------|-----------------------------|-----------------|
| Age at diagnosis, y | 64.5 (55-75) |
| >60 | n = 411 (85.4) |
| >65 | n = 260 (54.0) |
| >70 | n = 57 (10.6) |
| Follow-up, mo | 113.3 (0-204) |
| PSA levels at diagnosis, ng/mL | 7.2 (0.3-125) |
| >2.5 | n = 440 (91.5) |
| >4 | n = 333 (69.2) |
| >10 | n = 62 (12.9) |
| Gleason sum | |
| <7 | n = 199 (41.4) |
| =7 | n = 188 (39.1) |
| >7 | n = 28 (5.8) |
| Pathological T-stage (TNM 2002) | |
| T2a | n = 84 (17.5) |
| T2b | n = 10 (2.1) |
| T2c | n = 246 (51.1) |
| T3a | n = 93 (19.3) |
| T3b | n = 17 (3.5) |
| T4 | n = 28 (5.8) |
| Surgical margins | |
| Positive | n = 119 (24.7) |
| Negative | n = 362 (75.3) |
| Biochemical recurrence, mo | 40.9 (0-205) |
| Yes | n = 119 (24.7) |
| No | n = 362 (75.3) |
| Local recurrence, mo | 110.0 (6-146) |
| Yes | n = 24 (5.0) |
| No | n = 457 (95.0) |
| Overall death, mo | 113.7 (0-202) |
| Yes | n = 112 (23.3) |
| No | n = 368 (76.6) |

Abbreviation: PSA, prostrate specific antigen.
tissue when compared to NAP (\(P = 0.0015\)). Four other proteins (CD9, EEF1A2, UBA52, and BCAM) were not significantly differentially expressed in the tissue proteomics. The PCa-derived EV proteins VPS28 and ACTR3B were not identified in the tissue validation set. Proteins that were higher expressed in normal prostate cell line EVs were also cross-validated on MS-MS data of tissue samples and are shown in Table 1. Although 15 of the 34 were differentially expressed in both datasets, only 4 of the 15 showed the same direction of higher expressed in EVs from immortalized normal prostate epithelial cell lines and higher expressed in NAP tissue.

When expression of proteins was compared, XPO1 was significantly higher expressed in PCa (Figure 1B), but no difference (\(P = 0.696\)) was observed between low risk (GS 6) and intermediate/high-risk PCa (GS \(\geq 7\)) (Figure 1C). Interestingly, PDCD6IP was significantly lower expressed in intermediate/high risk in prostate tissue (\(P = 0.017\)) (Figure 1C).

3.2 | Protein expression by tissue microarray immunohistochemistry

For independent validation of XPO1 and PDCD6IP, immunohistochemistry (IHC) was performed on the TMA. Patient characteristics and clinicopathological parameters are shown in Table 2 and were previously published by Hoogland et al.\(^\text{16}\) Briefly, the mean age at the time of radical prostatectomy was 64.7 years; follow-up was 113.3 months. Gleason score after radical prostatectomy was <7 in 265 (55.1%), 7 in 188 (39.1%), and >7 in 28 (5.8%) patients. Surgical margins were negative in 362 (75.3%) patients. Biochemical recurrence was observed in 119 (24.7%) patients after an average of 40.9 months. Staining intensities of the candidate biomarkers could not be assessed in 57 of the 481 samples (11.8%) because the tumor was absent.

Antibody IHC verification and impression of the tissue staining of the three candidate protein markers was published previously and further expanded as depicted in Figure 2.\(^\text{7}\) XPO1, PDCD6IP, and FASN stainings were observed in all samples, mainly in epithelial cells. We noticed that the XPO1 expression varied within and between the nuclear and cytoplasmic compartments. Nuclear XPO1 expression was present in 98.4% of cases and cytoplasmic expression was observed in 74.5% of cases. XPO1 showed strong nuclear and low cytoplasmic expression in luminal cells in NAP.\(^\text{7}\) With the progression of PCa and increasing GS, cytoplasmic XPO1 expression increased (Figure 2). PDCD6IP showed high expression in both luminal and basal cells in NAP.

Subsequently, we evaluated the association between protein expression intensities of our three candidate biomarkers and PSA at diagnosis, GS, pT-stage, surgical margins, biochemical recurrence, local recurrence, overall death and PCa-related death (Tables 3, 4; Table S1). Nuclear XPO1 expression and PDCD6IP did not correlate with any clinicopathological parameter. High cytoplasmic XPO1 expression correlated with GS \(\geq 7\) (\(P = 0.002\)) and PCa-specific death after multivariate analysis (\(P = 0.009\)) (Table 4). All other parameters were not significantly different. The FASN TMA analyses have recently been published as part of the tissue proteomics study and revealed that expression among the PCa samples was higher in GS < 7 and GS = 7 (49.0% and 34.6%, respectively) than in GS > 7 (5.4%). This is in agreement with previous studies.\(^\text{6,19}\)
DISCUSSION

In this study we investigated whether previously identified PCa EV-derived proteins were differentially expressed in PCa tissue from patients using mass spectrometry and immunohistochemistry. We found that XPO1 was associated with PCa in mass spectrometry and with higher GS using IHC on our TMA. PDCD6IP was not associated with adverse clinicopathological characteristics.

XPO1 (also known as CRM1) mediates nuclear export of proteins and RNAs and its differential expression has been linked to multiple types of cancer.\(^{20-22}\) These transported proteins play a role in tumor signaling pathways, including the AR-pathway.\(^{23,24}\) XPO1 has already been identified as a marker for several malignancies.\(^{21}\) We identified this protein to be higher expressed in EVs derived from the VCaP PCa.

### TABLE 3

| Expression nuclear XPO1 | 0   | 1   | 2   | 3   | Total | P-value |
|--------------------------|-----|-----|-----|-----|-------|---------|
| PSA at diagnosis         |     |     |     |     |       |         |
| ≤10 ng/mL                | 5   | 66  | 217 | 119 | 396   | 0.012   |
| >10 ng/mL                | 1   | 16  | 35  | 8   | 60    |         |
| Total                    | 6   | 71  | 252 | 127 | 456   |         |
| Gleason score            |     |     |     |     |       |         |
| <7                       | 5   | 40  | 129 | 74  | 248   | 0.145   |
| 7                        | 0   | 26  | 105 | 50  | 181   |         |
| >7                       | 1   | 19  | 19  | 3   | 28    |         |
| Total                    | 6   | 71  | 253 | 127 | 457   |         |
| pT-stage                 |     |     |     |     |       |         |
| pT2                      | 5   | 49  | 177 | 93  | 324   | 0.345   |
| pT3a/b                   | 1   | 14  | 65  | 26  | 106   |         |
| pT4                      | 0   | 8   | 11  | 8   | 27    |         |
| Total                    | 6   | 71  | 253 | 127 | 457   |         |

Intensity was scored as negative (0; no staining), weak (1; only visible at high magnification), moderate (2; visible at low magnification), or strong (3; striking at low magnification). Staining intensities were correlated with patient characteristics after radical prostatectomy.

Abbreviation: PSA, prostate specific antigen.

### TABLE 4

|               | Univariate | Multivariate |
|---------------|------------|--------------|
| PSA at diagnosis |            |              |
| ≤10 ng/mL | 0.012 | 0.97 |
| >10 ng/mL | 0.345 | 0.97 |
| Total       | 0.221 |     |
| Gleason score |      |      |
| <7         | 0.002 | 0.221 |
| 7          | 0.002 | 0.221 |
| >7         | 0.002 | 0.221 |
| Total       | 0.221 |     |
| pT-stage    |            |              |
| pT2        | 0.012 | 0.97 |
| pT3a/b     | 0.345 | 0.97 |
| pT4        | 0.221 | 0.221 |
| Total       | 0.221 |     |

Univariate and multivariate correlation of clinicopathological parameters and staining intensities of PDCD6IP, nuclear XPO1, and cytoplasmic XPO1. A P-value < 0.05 was considered as statistically significant.

Abbreviation: HR, hazards ratio; PSA, prostrate specific antigen.
cell line. In this current study, we observed higher expression in PCa tissue as compared to NAP, which could explain the increased EV expression. From the TMA, we noticed that when GS increased, nuclear staining decreased and cytoplasmic XPO1 location increased. This provides us with an additional explanation for the increased presence of this 123 kDa nuclear export protein in EVs: a shift towards cytoplasmic expression could increase the random chance or even active escorting of XPO1 into extracellular vesicles.

When correlated to clinicopathological parameters, we observed a significant correlation between higher XPO1 cytoplasmic expression with higher GS (7 or higher) and disease-specific death. Therefore, this finding implies that there seems to be a clinical role as a tissue marker regarding prognosis for PCa. The correlation with disease-specific death could only be addressed in 12 patients. Because of the limited number of patients with PCa-related death, we should be careful to draw conclusions regarding the correlation of cytoplasmic XPO1 and this clinical parameter.

Interestingly, recent reports have been published on the functional role of XPO1 and the effect of cancer by inhibition of XPO1-mediated transport. Administration of selective inhibitors of nuclear transport (SINE) such as Selinexor, have led to an enrichment of tumor suppressor proteins in the nucleus. This subsequently resulted in apoptosis, reduction of tumor spreading and improved overall survival in preclinical models in PCa. Clinical studies are being performed to reveal the real potential of XPO1-directed therapy.

FASN has already been described as a potential marker for PCa. A recent study by Hamada et al showed that expression of this protein on biopsies could be a marker for the upgrading of GS after radical prostatectomy. Furthermore, Wu et al showed that this protein is useful for the diagnosis of PCa. However, both studies were performed on relatively small groups (<100 patient samples). Although we previously showed higher expression of FASN in PCa EVs, Rodriguez-Blanco et al could only observe a statistically significant difference with normal prostate tissue in our TMA. When expression was compared with clinicopathological parameters, no statistically significant difference was observed. So far, FASN could be used as a marker for the diagnosis PCa, but the expression in normal cells is also relatively high. This makes it difficult for distinguishing between disease and healthy tissue.

PDCD6IP has scarcely been reported as a tumor marker or as having a role in tumor biology. PDCD6IP (also referred to as ALIX) is involved in endocytosis, multivesicular body biogenesis, apoptosis, membrane repair, and directly related to EV formation. Although PDCD6IP is used as a general marker for EVs, the transformation of healthy cells to cancerous cells could interfere with EV formation and therefore the presence of PDCD6IP could be altered. Our current study showed no statistical difference of expression between NAP and PCa tissue, nor did we find decreased PDCD6IP expression in patients with GS≥7 in our TMA. Furthermore, PDCD6IP did not correlate to any clinicopathological parameters. We conclude that over-representation of PDCD6IP in EVs from VCaP and PC346c is not explained by a general higher expression of this protein in PCa.

Although PDCD6IP differential expression in EVs could not be validated with tissue MS-MS and TMA IHC, it would be interesting to see whether this marker still shows clinical potential when an easily applicable EV-specific assay (such as an ELISA) is applied.

From our mass spectrometry and TMA analyses, we have learned that overexpression and cytoplasmic compartmentalization provides an explanation for the increased presence of XPO1 in PCa-derived EVs. The absence of a correlation between tissue and EV expression for PDCD6IP suggest that also other mechanisms play a role in EV-mediated secretion. The most obvious would be specific escorting of proteins in extracellular vesicles via the ESCRT system. Whether this pathway is changed in cancer development and progression is not fully known.

Besides XPO1, FASN, and PDCD6IP, our analyses also provided more data for new candidate EV biomarkers: The 16 additional proteins that were identified in EVs and also differentially expressed in the tissue MS analyses. It is worthwhile to investigate whether these PCa tissue-dysregulated, EV-detectable proteins are EV biomarkers in other cell lines and in clinical samples. From this list, PABPC1, CLIC1, RAB10, and PKM2 have been identified as a potential marker for (prostate) cancer. High expression of ANXA2 has been shown to have an unfavorable prognosis in multiple malignancies. With this group of potential biomarkers, it is of interest to note that the level of expression in EVs from normal versus PCa cell lines is not always in the same direction as the NAP versus PCa tissue MS (Table 1). Besides the comparison of a few 2D grown cell lines with patient tissue samples, changes in cytoplasmic subcellular location and specific EV sorting of proteins can explain such apparent discrepancies.

XPO1, FASN, and PDCD6IP are known or expected to be intra-vesicular proteins and a detection assay to determine their levels in EVs from bodyfluids will likely involve multiple steps: EV isolation and disruption followed by protein measurement using enzyme-linked immunosorbent assays (ELISA), related immune-assays or mass spectrometry. Robust and reproducible EV isolation and protein assays are still under development and until these technologies are standardized, large scale intra-vesicular protein biomarker validation and clinical implementation are difficult to realize. This is different for EV membrane-associated proteins that can be detected with antibodies while the vesicle remains intact. Standard ELISA-like assays might capture and detect the EV protein of interest, directly from biofluids.

## 5 CONCLUSIONS

In this study, we investigated previously-identified EV-derived markers on large cohorts of patient tissue samples for validation of diagnostic and prognostic differential expression. High expression of cytoplasmic XPO1 shows a strong correlation with PCa progression, while no differential tissue expression of PDCD6IP was observed. The increase in cytoplasmic XPO1 during the progression of PCa can explain the higher abundance in secreted EVs.
REFERENCES

1. Ruben O, Meehan K. Tumour-derived extracellular vesicles as a novel source of protein biomarkers for cancer diagnosis and monitoring. Proteomics. 2018;19(1-2):e1800155.

2. Minciacchi VR, Zijlstra A, Rubin MA, Di Vizio D. Extracellular vesicles for liquid biopsy in prostate cancer: where are we and where are we headed? Prostate Cancer Prostatic Dis. 2017;20(3):251-258.

3. Duijvesz D, Luider T, Bangma CH, Jenster G. Exosomes as biomarker treasure chests for prostate cancer. Eur Urol. 2011;59(5):823-831.

4. Khan S, Jutzy JM, Valenzuela MM, et al. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLOS One. 2012;7(10):e46737.

5. Hessvik NP, Phuyal S, Brech A, Sandvig K, Llorente A. Profiling of microRNAs in exosomes released from PC-3 prostate cancer cells. Biochim Biophys Acta. 2012;1819(11-12):1154-1163.

6. Hosseini-Behesti E, Pham S, Adomat H, Li N, Tomlinson Guns ES. Exosomes as biomarker enriched microvesicles: characterization of exosomal proteins derived from a panel of prostate cell lines with distinct AR phenotypes. Mol Cell Proteomics. 2012;11(10):863-885.

7. Duijvesz D, Burnum-Johnson KE, Gritsenko MA, et al. Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer. PLOS One. 2013;8(12):e82589.

8. Nilsson J, Skog J, Nordstrand A, et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br J Cancer. 2009;100(10):1603-1607.

9. Fujita K, Kume H, Matsuzaki K, et al. Proteomic analysis of urinary extracellular vesicles from high Gleason score prostate cancer. Sci Rep. 2017;7:42961.

10. Xu Y, Qin S, An T, Tang Y, Huang Y, Zheng L. MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method. Prostate. 2017;77(10):1167-1175.

11. McKiernan J, Donovan MJ, O’Neill V, et al. A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy. JAMA Oncol. 2016;2(7):882-889.

12. Wang L, Skotland T, Berge V, Sandvig K, Llorente A. Exosomal proteins as prostate cancer biomarkers in urine: from mass spectrometry discovery to immunoassay-based validation. Eur J Pharm Sci. 2017;98:80-85.

13. Giovanni Rodríguez-Blanco Lc, Duijvesz Diederick, Hoogland AMarije, et al. Tissue proteomics outlines AGR2 AND LOX5 as markers for biochemical recurrence of prostate cancer. Oncotarget. 2018;9:36444-36456.

14. Singh V, Stoop MP, Stiingl C, et al. Cerebrosplinal-fluid-derived immunoglobulin G of different multiple sclerosis patients shares mutated sequences in complementarity determining regions. Mol Cell Proteomics. 2013;12(12):3924-3934.

15. Stoop MP, Rosenling T, Attali A, et al. Minocycline effects on the cerebrosplinal fluid proteome of experimental autoimmune encephalomyelitis rats. J Proteome Res. 2012;11(8):4315-4325.

16. Hoogland AM, Jenster G, van Weerden WM, et al. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod Pathol. 2012;25(3):471-479.

17. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320-1328.

18. Hoogland AM, Jenster G, van Weerden WM, et al. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod Pathol. 2011;24:1511-1520.

19. Rodriguez-Blanco GZL, Duijvesz D, Hoogland AM, et al. Tissue proteomics outlines AGR2 AND LOX5 as markers for biochemical recurrence of prostate cancer. Oncotarget. 2018;9(92):36444-36456.

20. Huang WY, Yue L, Qiu WS, Wang LW, Zhou XH, Sun YJ. Prognostic value of CRM1 in pancreas cancer. Clin Invest Med. 2009;32(6):E315.

21. Noske A, Weichert W, Niesporek S, et al. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer. 2008;112(8):1733-1743.

22. Yao Y, Dong Y, Lin F, et al. The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep. 2009;21(1):229-235.

23. Stade K, Ford CS, Guthrie C, Weis K. Exportin 1 (Crmp1) is an essential nuclear export factor. Cell. 1997;90(6):1041-1050.

24. Saporita AJ, Zhang Q, Navai N, et al. Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor. J Biol Chem. 2003;278(43):41998-42005.

25. Parikh K, Cang S, Sekhri A, Liu D. Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents. J Hematol Oncol. 2014;7:78.

26. Abuokameel A, Muqbil I, Baloglu E, et al. Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression. Oncotarget. 2018;9(82):35327-35342.

27. Gravina GL, Tortoreto M, Mancini A, et al. XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa). J Hematol Oncol. 2014;7:46.

28. Mendonca J, Sharma A, Kim HS, et al. Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer. Oncotarget. 2014;5(15):6102-6112.

29. Liu H, Liu JY, Wu X, Zhang JT. Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker. Int J Biochem Mol Biol. 2010;1(1):69-89.

30. Migita T, Ruiz S, Fornari A, et al. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst. 2009;101(7):519-532.

31. Hamada S, Horiguchi A, Kuroda K, et al. Elevated fatty acid synthase (FASN) expression in prostate needle biopsy cores predicts upgraded Gleason score in radical prostatectomy specimens. Prostate. 2014;74(1):90-96.

32. Wu X, Qin L, Fako V, Zhang JT. Molecular mechanisms of fatty acid synthase (FASN)-mediated resistance to anti-cancer treatments. Adv Biol Regul. 2014;54:214-221.

33. Odorizzi G. The multiple personalities of Alix. J Cell Sci. 2006;119(Pt 15):3025-3032.

34. Colombo M, Maita C, van Niel G, et al. Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles. J Cell Sci. 2013;126(Pt 24):5553-5565.

35. Babst M. MVBE vesicle formation: ESCRT-dependent, ESCRT-independent and everything in between. Curr Opin Cell Biol. 2011;23(4):452-457.

36. Schmidt O, Teis D. The ESCRT machinery. Curr Biol. 2012;22(4):R116-R120.

37. Tanaka N, Kyouuma M, Sugamura K. Endosomal sorting complex required for transport proteins in cancer pathogenesis, vessel identification.
transport, and non-endosomal functions. Cancer Sci. 2008;99(7):1293-1303.

38. Polo A, Marchese S, De Petro G, et al. Identifying a panel of genes/proteins/miRNAs modulated by arsenicals in bladder, prostate, kidney cancers. Sci Rep. 2018;8(1):10395.

39. Singha B, Harper SL, Goldman AR, et al. CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer. Sci Rep. 2018;8(1):14725.

40. Wang W, Jia WD, Hu B, Pan YY. RAB10 overexpression promotes tumor growth and indicates poor prognosis of hepatocellular carcinoma. Oncotarget. 2017;8(16):26434-26447.

41. Talesa VN, Ferri I, Bellezza G, Love HD, Sidoni A, Antognelli C. Glyoxalase 2 Is involved in human prostate cancer progression as part of a mechanism driven by PTEN/PI3K/AKT/mTOR signaling with involvement of PKM2 and ERalpha. Prostate. 2017;77(2):196-210.

42. Christensen MV, Hogdall CK, Jochumsen KM, EVS Hogdall. Annexin A2 and cancer: a systematic review. Int J Oncol. 2018;52(1):5-18.

43. Duijvesz D, Versluis CY, van der Fels CA, et al. Immuno-based detection of extracellular vesicles in urine as diagnostic marker for prostate cancer. Int J Cancer. 2015;137(12):2869-2878.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Duijvesz D, Rodriguez-Blanco G, Hoogland AM, et al. Differential tissue expression of extracellular vesicle-derived proteins in prostate cancer. The Prostate. 2019;79:1032-1042. https://doi.org/10.1002/pros.23813